Free Trial

AstraZeneca (AZN) Stock Price, News & Analysis

$77.13
-0.21 (-0.27%)
(As of 07/8/2024 ET)
Today's Range
$77.04
$77.66
50-Day Range
$75.76
$80.83
52-Week Range
$60.47
$80.86
Volume
2.70 million shs
Average Volume
2.88 million shs
Market Capitalization
$239.14 billion
P/E Ratio
37.81
Dividend Yield
2.50%
Price Target
$88.00

AstraZeneca MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.91 Rating Score
Upside/​Downside
14.1% Upside
$88.00 Price Target
Short Interest
Healthy
0.26% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
1.04mentions of AstraZeneca in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
15.59%
From $4.04 to $4.67 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.80 out of 5 stars

Medical Sector

205th out of 876 stocks

Pharmaceutical Preparations Industry

89th out of 416 stocks

AZN stock logo

About AstraZeneca Stock (NASDAQ:AZN)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AZN Stock Price History

AZN Stock News Headlines

Eli Lilly and Company logo sign on World Headquarters
Eli Lilly's Stock Surge Driven by GLP-1 Demand (AZN)
Shares of Eli Lilly stock are about to hit a new all-time high, sponsored by the pending approval of new weight loss drugs
Bitcoin’s Biggest Year Yet
2024 is set to be a historic year for Bitcoin. It’s all thanks to three major catalysts that I reveal in my newest video.
The Only Energy Play You Should Be Looking At
Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has already inked deals with the Department of Energy.
See More Headlines
Receive AZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
4/25/2024
Today
7/08/2024
Next Earnings (Confirmed)
7/25/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:AZN
Employees
89,900
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$88.00
High Stock Price Target
$97.00
Low Stock Price Target
$82.00
Potential Upside/Downside
+14.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.91
Research Coverage
11 Analysts

Profitability

Net Income
$5.96 billion
Pretax Margin
15.62%

Debt

Sales & Book Value

Annual Sales
$45.81 billion
Cash Flow
$5.38 per share
Book Value
$12.63 per share

Miscellaneous

Outstanding Shares
3,100,510,000
Free Float
N/A
Market Cap
$239.14 billion
Optionable
Optionable
Beta
0.45

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

Should I Buy AstraZeneca Stock? AZN Pros and Cons Explained

Pros

Here are some ways that investors could benefit from investing in AstraZeneca:

  • AstraZeneca has shown consistent growth in revenue and earnings, with a positive EPS that has exceeded analysts' estimates.
  • The company has a strong return on equity of 30.42%, indicating efficient use of shareholder funds to generate profits.
  • Analysts have set a high price target for AstraZeneca, indicating positive sentiment and potential for stock price appreciation.
  • AstraZeneca's current stock price is trading near its 12-month high, reflecting positive market sentiment and potential for further gains.
  • The company's focus on the discovery, development, and commercialization of prescription medicines positions it well in the healthcare sector, which is known for its stability and long-term growth potential.

Cons

Investors should be bearish about investing in AstraZeneca for these reasons:

  • AstraZeneca's current stock price is trading near its 12-month high, which may indicate limited short-term upside potential.
  • The company's debt-to-equity ratio of 0.73 may raise concerns about its financial leverage and ability to manage debt obligations.
  • While the company has a strong PE ratio of 37.65, investors should be cautious of potential valuation risks associated with high PE ratios.
  • AstraZeneca's beta of 0.45 suggests lower volatility compared to the market, which may limit potential returns for more risk-tolerant investors.
  • Investors should consider the competitive landscape in the pharmaceutical industry and potential regulatory challenges that could impact AstraZeneca's future growth prospects.
These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, July 7, 2024. Please send any questions or comments about these AstraZeneca pros and cons to contact@marketbeat.com.

AZN Stock Analysis - Frequently Asked Questions

How have AZN shares performed this year?

AstraZeneca's stock was trading at $67.35 at the beginning of the year. Since then, AZN stock has increased by 14.5% and is now trading at $77.13.
View the best growth stocks for 2024 here
.

How were AstraZeneca's earnings last quarter?

AstraZeneca PLC (NASDAQ:AZN) posted its quarterly earnings results on Thursday, April, 25th. The company reported $1.03 earnings per share for the quarter, beating analysts' consensus estimates of $0.95 by $0.08. The firm had revenue of $12.68 billion for the quarter, compared to the consensus estimate of $11.92 billion. AstraZeneca had a net margin of 13.30% and a trailing twelve-month return on equity of 30.42%.

When did AstraZeneca's stock split?

AstraZeneca's stock split on the morning of Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly minted shares were payable to shareholders after the market closes on Friday, July 24th 2015. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What is Pascal Soriot's approval rating as AstraZeneca's CEO?

2,350 employees have rated AstraZeneca Chief Executive Officer Pascal Soriot on Glassdoor.com. Pascal Soriot has an approval rating of 98% among the company's employees. This puts Pascal Soriot in the top 20% of approval ratings compared to other CEOs of publicly-traded companies. 87.0% of employees surveyed would recommend working at AstraZeneca to a friend.

Does AstraZeneca have any subsidiaries?

AstraZeneca subsidiaries include Alexion Pharmaceuticals, Takeda Respiratory Business, AcertaPharma, ZS Pharma, Almirall, Pearl Therapeutics, Omthera Pharmaceuticals, and others.

Who are AstraZeneca's major shareholders?

Top institutional investors of AstraZeneca include M&R Capital Management Inc., Transcend Capital Advisors LLC, Boston Common Asset Management LLC and First Hawaiian Bank.
View institutional ownership trends
.

How do I buy shares of AstraZeneca?

Shares of AZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of AstraZeneca own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AstraZeneca investors own include Moderna (MRNA), Novavax (NVAX), Regeneron Pharmaceuticals (REGN), Albertsons Companies (ACI), American Airlines Group (AAL), Blue Apron (APRN) and BlackBerry (BB).

This page (NASDAQ:AZN) was last updated on 7/9/2024 by MarketBeat.com Staff

From Our Partners